Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02710396
Title Genetic Predictors of Benefit to Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University

head and neck cancer

bladder urothelial carcinoma

esophagus squamous cell carcinoma

lung non-small cell carcinoma


Carboplatin + Pembrolizumab + Pemetrexed Disodium


Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST